PCM
KURA icon

Pathway Capital Management’s Kura Oncology KURA Stock Holding History

Pathway Capital Management’s Portfolio KURA Stock Details KURA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-61,638
Closed -$848K – 7
2019
Q4 		$848K Buy
+61,638
New +$913K 0.43% 9

Other funds holding KURA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
CTA
Carillon Tower Advisers St. Petersburg, Florida $16.4B AUM 64.75% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Pathway Capital Management's KURA Position: Q1 2020 in Review

Pathway Capital Management sold out of Kura Oncology (KURA) in Q1 2020, closing a stake of 61,638 shares — an estimated $848K sold.

Pathway Capital Management first reported a position in KURA in Q4 2019 and held it in 1 quarter. The position peaked at $848K in Q4 2019. 119 funds tracked by Wall St. Rank hold KURA as of Q1 2020.

  • Pathway Capital Management reported no remaining Kura Oncology position as of Q1 2020 after selling out during the quarter.
  • Pathway Capital Management sold 61,638 Kura Oncology shares in Q1 2020, an estimated $848K.
  • Pathway Capital Management first reported a position in Kura Oncology in Q4 2019 and held it in 1 quarter.
  • Pathway Capital Management's Kura Oncology position peaked at $848K in Q4 2019.
  • 119 funds tracked by Wall St. Rank held Kura Oncology as of Q1 2020.

Based on Pathway Capital Management's 13F filing for Q1 2020, filed 4 May 2020.